ProMIS Neurosciences is trading at $14.00 (+5.26%) as investors continue to react to recent PMN310 clinical data showing the first human evidence of amyloid-beta oligomer target engagement.
- The stock's upward move follows a July 16 update highlighting positive clinical progress, which has sustained investor interest despite some recent profit-taking volatility following the prior rally.
- Broader biotech sentiment is also supportive, with the XBI up 2.17% and sector-wide momentum driven by recent M&A activity, though the primary catalyst remains company-specific clinical milestones.